文献速递浆细胞疾病造血干细胞移植与细胞治疗

硼替佐米、来那度胺和地塞米松作为多发性骨髓瘤自体移植前诱导治疗

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
PubMed 文献 · Blood · 2019-01-01

PETHEMA/GEM2012 3期研究纳入458例≤65岁新诊断多发性骨髓瘤患者,评估6周期皮下硼替佐米+来那度胺+地塞米松(VRD)诱导后行自体干细胞移植(ASCT),移植后2周期VRD巩固。缓解随时间加深,诱导后完全缓解率33.4%,高危细胞遗传学患者相似(34.8%),ASCT后44.1%,巩固后50.2%;微小残留病(MRD)检测不到率从诱导28.8%升至移植42.1%和巩固45.2%。

要点

  • VRD诱导后≥非常好的部分缓解率70.4%,完全缓解率33.4%。
  • ASCT和巩固治疗后缓解继续加深,MRD阴性率提高至45.2%。
  • 诱导期间≥3级不良事件常见为中性粒细胞减少12.9%和感染9.2%,≥2级周围神经病变17.0%。

核心结论

  • VRD是NDMM有效且耐受良好的诱导方案,诱导期间及后续治疗中缓解持续加深。

研究设计与样本

  • 3期PETHEMA/GEM2012研究纳入458例≤65岁新诊断多发性骨髓瘤患者,接受6周期皮下硼替佐米+来那度胺+地塞米松诱导,随后ASCT(白消安+美法仑或美法仑预处理),移植后2周期VRD巩固。

主要发现

  • 在启动第6周期诱导的患者(n=426)中,≥非常好的部分缓解率在第3周期为55.6%,第4周期63.8%,第5周期68.3%,诱导后70.4%。
  • 意向治疗(ITT)人群诱导后完全缓解率33.4%,在高危细胞遗传学患者(n=92)中为34.8%,ASCT后44.1%,巩固后50.2%。
  • ITT人群MRD检测不到率(中位灵敏度3×10-6)从诱导后28.8%升至移植后42.1%和巩固后45.2%。
  • 诱导期间最常见的≥3级治疗中出现的不良事件为中性粒细胞减少(12.9%)和感染(9.2%);≥2级周围神经病变(分组术语)为17.0%,3级3.7%,4级0.2%。

临床怎么用

  • VRD可作为适合移植的新诊断多发性骨髓瘤患者的诱导方案,诱导后缓解可随ASCT和巩固治疗进一步加深。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Achieving and maintaining a high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma (NDMM). The phase 3 PETHEMA/GEM2012 study, in 458 patients aged ≤65 years with NDMM, is evaluating bortezomib (subcutaneous) + lenalidomide + dexamethasone (VRD) for 6 cycles followed by autologous stem cell transplant (ASCT) conditioned with IV busulfan + melphalan vs melphalan and posttransplant consolidation with 2 cycles of VRD. We present grouped response analysis of induction, transplant, and consolidation. Responses deepened over time; in patients who initiated cycle 6 of induction (n = 426), the rates of a very good partial response or better were 55.6% by cycle 3, 63.8% by cycle 4, 68.3% by cycle 5, and 70.4% after induction. The complete response rate of 33.4% after induction in the intent-to-treat (ITT) population, which was similar in the 92 patients with high-risk cytogenetics (34.8%), also deepened with further treatment (44.1% after ASCT and 50.2% after consolidation). Rates of undetectable minimal residual disease (median 3 × 10-6 sensitivity) in the ITT population also increased from induction (28.8%) to transplant (42.1%) and consolidation (45.2%). The most common grade ≥3 treatment-emergent adverse events during induction were neutropenia (12.9%) and infection (9.2%). Grade ≥2 peripheral neuropathy (grouped term) during induction was 17.0%, with a low frequency of grade 3 (3.7%) and grade 4 (0.2%) events. VRD is an effective and well-tolerated regimen for induction in NDMM with deepening response throughout induction and over the course of treatment. This trial was registered at www.clinicaltrials.gov as #NCT01916252 and EudraCT as #2012-005683-10.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Rosiñol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019. PMID: 31484647. doi:10.1182/blood.2019000241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。